Nephris
1 known investors
Find your way into Nephris
Sign up to see every warm intro you have to Nephris
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nephris team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nephris is a biotech company developing first-in-class therapies for diabetic chronic kidney disease. It focuses on research and innovation for patients with diabetic renal disease.
Investors · 1
Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M
How we know: Sofinnova Partners's portfolio page · funding news · finance.yahoo.com · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeed FinancingApr 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Nephris do?
- Nephris is a biotech company developing first-in-class therapies for diabetic chronic kidney disease. It focuses on research and innovation for patients with diabetic renal disease.
- Who are Nephris's investors?
- Nephris's investors include Sofinnova Partners.
